{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:34:38Z","timestamp":1793331278374,"version":"4.5.0"},"reference-count":20,"publisher":"American Diabetes Association","issue":"6","license":[{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6,2]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To examine the effect of SGLT2 inhibitors (SGLT2i) on endogenous glucose production (EGP) in patients with type 2 diabetes after an oral glucose load.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Forty-eight patients with type 2 diabetes received an 8-h [3-3H]-glucose infusion (protocol I) to assess EGP response to: 1) dapagliflozin (DAPA), 10 mg; 2) exenatide (EXE), 5 \u03bcg s.c.; 3) DAPA\/EXE; and 4) placebo (PCB). After 2 weeks (protocol II), patients were restudied with a 5-h double-tracer (i.v. [3-3H]-glucose and oral [1-14C]-glucose) oral glucose tolerance test (OGTT) preceded by PCB, DAPA, EXE, or DAPA\/EXE.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Protocol I: EGP decreased (P &amp;lt; 0.01) with PCB (2.16 \u00b1 0.15 to 1.57 \u00b1 0.08 mg\/kg\/min) and EXE (2.13 \u00b1 0.16 to 1.58 \u00b1 0.03) and remained unchanged (P = NS) with DAPA (2.04 \u00b1 0.17 vs. 1.94 \u00b1 0.18) and DAPA\/EXE (2.13 \u00b1 0.10 vs. 2.09 \u00b1 0.03). During OGTT, EGP decreased (P &amp;lt; 0.01) with PCB (2.30 \u00b1 0.05 to. 1.45 \u00b1 0.06 mg\/kg\/min) and EXE (2.53 \u00b1 0.08 to 1.36 \u00b1 0.06); with DAPA (2.20 \u00b1 0.04 vs. 1.71 \u00b1 0.07) and DAPA\/EXE (2.48 \u00b1 0.05 vs. 1.64 \u00b1 0.07), the decrease in EGP was attenuated (both P &amp;lt; 0.05). During OGTT, the insulin\/glucagon (INS\/GCN) ratio increased in PCB (0.26 \u00b1 0.03 vs. 0.71 \u00b1 0.06 \u03bcU\/mL per pg\/mL), whereas in DAPA (0.26 \u00b1 0.02 to 0.50 \u00b1 0.04), the increase was blunted (P &amp;lt; 0.05). In EXE, INS\/GCN increased significantly (0.32 \u00b1 0.03 to 1.31 \u00b1 0.08) and was attenuated in DAPA\/EXE (0.32 \u00b1 0.03 vs. 0.78 \u00b1 0.08) (P &amp;lt; 0.01).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>These findings provide novel evidence that the increase in EGP induced by SGLT2i is present during an oral glucose load. The fact that stimulation of EGP occurs despite elevated plasma insulin and glucagon suggests that additional factors must be involved.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc21-1798","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T19:45:58Z","timestamp":1646250358000},"page":"1372-1380","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":11,"title":["Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose"],"prefix":"10.2337","volume":"45","author":[{"given":"Mariam","family":"Alatrach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Agyin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6215-9418","authenticated-orcid":false,"given":"Carolina","family":"Solis-Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Lavryneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Gastaldelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Triplitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8581-6273","authenticated-orcid":false,"given":"Ralph A.","family":"DeFronzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2573-0208","authenticated-orcid":false,"given":"Eugenio","family":"Cersosimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"key":"2022060218525719300_B1","first-page":"81","article-title":"Renal glucose handling and the kidney as a target for anti-diabetic medication","volume":"7","author":"Cersosimo","year":"2014","journal-title":"Curr Trends Endocrinol"},{"key":"2022060218525719300_B2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2022060218525719300_B3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest"},{"key":"2022060218525719300_B4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"2022060218525719300_B5","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.2337\/db13-0604","article-title":"Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans","volume":"62","author":"Abdul-Ghani","year":"2013","journal-title":"Diabetes"},{"key":"2022060218525719300_B6","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2337\/db19-0770","article-title":"Evidence against an important role of plasma insulin and glucagon concentrations in the increase in EGP caused by SGLT2 inhibitors","volume":"69","author":"Alatrach","year":"2020","journal-title":"Diabetes"},{"key":"2022060218525719300_B7","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.2337\/db17-1278","article-title":"Endogenous glucose production and hormonal changes in response to canagliflozin and liraglutide combination therapy","volume":"67","author":"Martinez","year":"2018","journal-title":"Diabetes"},{"key":"2022060218525719300_B8","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.2337\/dc19-1993","article-title":"Clinical parameters, fuel oxidation and glucose kinetics in type 2 diabetes patients treated with dapagliflozin plus saxagliptin","volume":"43","author":"Qin","year":"2020","journal-title":"Diabetes Care"},{"key":"2022060218525719300_B9","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1007\/s00125-020-05254-w","article-title":"Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy","volume":"63","author":"Daniele","year":"2020","journal-title":"Diabetologia"},{"key":"2022060218525719300_B10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0026-0495(88)90033-9","article-title":"The disposal of an oral glucose load in patients with non-insulin-dependent diabetes","volume":"37","author":"Ferrannini","year":"1988","journal-title":"Metabolism"},{"key":"2022060218525719300_B11","doi-asserted-by":"crossref","first-page":"E409","DOI":"10.1210\/jc.2012-3056","article-title":"Pathogenesis of prediabetes: role of the liver in isolated fasting hyperglycemia and combined fasting and postprandial hyperglycemia","volume":"98","author":"Basu","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2022060218525719300_B12","doi-asserted-by":"crossref","first-page":"580","DOI":"10.2337\/diab.34.6.580","article-title":"The disposal of an oral glucose load in healthy subjects. A quantitative study","volume":"34","author":"Ferrannini","year":"1985","journal-title":"Diabetes"},{"key":"2022060218525719300_B13","doi-asserted-by":"crossref","first-page":"E846","DOI":"10.1152\/ajpendo.00030.2008","article-title":"Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes","volume":"294","author":"Cervera","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022060218525719300_B14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1152\/ajplegacy.1956.187.1.15","article-title":"Measurement of size and turnover rate of body glucose pool by the isotope dilution method","volume":"187","author":"Steele","year":"1956","journal-title":"Am J Physiol"},{"key":"2022060218525719300_B15","doi-asserted-by":"crossref","first-page":"314","DOI":"10.2174\/1573399814666180813124645","article-title":"Hormonal, metabolic and hemodynamic adaptations to glycosuria in type 2 diabetes patients treated with sodium-glucose co-transporter inhibitors","volume":"15","author":"Cersosimo","year":"2019","journal-title":"Curr Diabetes Rev"},{"key":"2022060218525719300_B16","doi-asserted-by":"crossref","first-page":"e12610","DOI":"10.14814\/phy2.12610","article-title":"Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study","volume":"3","author":"Acosta","year":"2015","journal-title":"Physiol Rep"},{"key":"2022060218525719300_B17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/dom.12589","article-title":"Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes","volume":"18","author":"Fulcher","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2022060218525719300_B18","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.2337\/dc12-2391","article-title":"Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study","volume":"36","author":"Polidori","year":"2013","journal-title":"Diabetes Care"},{"key":"2022060218525719300_B19","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2337\/dc11-0291","article-title":"Effects of exenatide on measures of \u03b2-cell function after 3 years in metformin-treated patients with type 2 diabetes","volume":"34","author":"Bunck","year":"2011","journal-title":"Diabetes Care"},{"key":"2022060218525719300_B20","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","article-title":"Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial","volume":"4","author":"Fr\u00edas","year":"2016","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/45\/6\/1372\/684248\/dc211798.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/45\/6\/1372\/684248\/dc211798.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T18:53:33Z","timestamp":1654196013000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/45\/6\/1372\/144631\/Dapagliflozin-Impairs-the-Suppression-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,2]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3,2]]},"published-print":{"date-parts":[[2022,6,2]]}},"URL":"https:\/\/doi.org\/10.2337\/dc21-1798","relation":{},"ISSN":["0149-5992"],"issn-type":[{"value":"0149-5992","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,2]]}}}